sc 58125 has been researched along with lipoxin a4 in 1 studies
| Studies (sc 58125) | Trials (sc 58125) | Recent Studies (post-2010) (sc 58125) | Studies (lipoxin a4) | Trials (lipoxin a4) | Recent Studies (post-2010) (lipoxin a4) |
|---|---|---|---|---|---|
| 93 | 0 | 15 | 833 | 17 | 398 |
| Protein | Taxonomy | sc 58125 (IC50) | lipoxin a4 (IC50) |
|---|---|---|---|
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | 0.0001 | |
| N-formyl peptide receptor 2 | Homo sapiens (human) | 0.0119 | |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | 0.0001 | |
| Transcription factor p65 | Homo sapiens (human) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
1 other study(ies) available for sc 58125 and lipoxin a4
| Article | Year |
|---|---|
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |